BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Lymphoma Research Foundation - ECPv6.18.3.1//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-ORIGINAL-URL:https://lymphoma.org
X-WR-CALDESC:Events for Lymphoma Research Foundation
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:America/New_York
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20250309T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20251102T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20260308T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20261101T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20270314T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20271107T060000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20260811T163000
DTEND;TZID=America/New_York:20260811T183000
DTSTAMP:20260618T180226Z
CREATED:20260618T180224Z
LAST-MODIFIED:20260618T180226Z
UID:10000268-1786465800-1786473000@lymphoma.org
SUMMARY:Ask the Doctor About Lymphoma: Navigating Relapsed/Refractory Disease
DESCRIPTION:Ask the Doctor About Lymphoma is a virtual two-hour program that combines a comprehensive and accessible overview of lymphoma by an expert with an extensive question-and-answer session. This program will provide patients with information on what to consider if their lymphoma or CLL/SLL has returned or is not responding to initial treatment. \n\n\n\n\nDefining Relapsed/Refractory Lymphoma\n\n\n\nTreatment Options: What is the next step after relapse?\n\n\n\nThe Role of Clinical Trials in Relapsed/Refractory Lymphoma Care\n\n\n\nTips for Communicating with Your Healthcare Team\n\n\n\nQuestion and Answer Session
URL:https://lymphoma.org/event/ask-the-doctor-about-lymphoma-navigating-relapsed-refractory-disease/
LOCATION:New York
CATEGORIES:Patient & Care Partner Education
ATTACH;FMTTYPE=image/jpeg:https://lymphoma.org/wp-content/uploads/2026/06/AdobeStock_260037109-scaled.jpeg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20260820T180000
DTEND;TZID=America/New_York:20260820T203000
DTSTAMP:20260618T182852Z
CREATED:20260618T182850Z
LAST-MODIFIED:20260618T182852Z
UID:10000270-1787248800-1787257800@lymphoma.org
SUMMARY:Lymphoma Talk: Los Angeles
DESCRIPTION:Lymphoma Talk is a two-hour weekday evening in-person program led by lymphoma experts that provides information about lymphoma in three breakout sessions.
URL:https://lymphoma.org/event/lymphoma-talk-los-angeles-2/
LOCATION:Westdrift Manhattan Beach\, 1400 Parkview Avenue\, Manhattan Beach\, California\, 90266
CATEGORIES:Patient & Care Partner Education
ATTACH;FMTTYPE=image/jpeg:https://lymphoma.org/wp-content/uploads/2026/06/Lymphoma_594-scaled.jpg
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20260826T143000
DTEND;TZID=America/New_York:20260826T154500
DTSTAMP:20260618T183831Z
CREATED:20260618T183828Z
LAST-MODIFIED:20260618T183831Z
UID:10000274-1787754600-1787759100@lymphoma.org
SUMMARY:Update on Diffuse Large B-Cell Lymphoma (DLBCL)
DESCRIPTION:Webinars are hour-long interactive programs discussing the diagnosis and treatment of specific lymphoma subtypes and key research and treatment updates. Webinars feature a presentation from the featured expert\, with the remainder of the time allocated to an extensive Q&A session. \n\n\n\n\nDiagnosis\, Staging\, and Classification of Diffuse Large B-Cell Lymphoma (DLBCL)\n\n\n\nApproach to First-line Treatment\n\n\n\nTiming of Relapse and Second-Line Treatment\n\n\n\nThird-Line Treatment and Treatment Options Under Investigation\n\n\n\nSide Effects and Quality-of-Life Concerns\n\n\n\nQuestion and Answer Session
URL:https://lymphoma.org/event/update-on-diffuse-large-b-cell-lymphoma-dlbcl/
LOCATION:New York
CATEGORIES:Patient & Care Partner Education
ATTACH;FMTTYPE=image/jpeg:https://lymphoma.org/wp-content/uploads/2026/06/AdobeStock_387932268-scaled.jpeg
END:VEVENT
END:VCALENDAR